Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Revenue - Disaggregation of Revenue (Details)

v3.24.3
Note 3 - Revenue - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Total revenue $ 0 $ 19,520 $ 53 $ 41,511
Pfizer [Member]        
Total revenue 0 9,179 6 14,088
Astra Zeneca A B [Member]        
Total revenue 0 3,909 0 8,399
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member]        
Total revenue 0 3,951 47 3,846
Genentech [Member]        
Total revenue 0 0 0 12,697
Boston Pharmaceuticals [Member]        
Total revenue $ 0 $ 2,481 $ 0 $ 2,481